ALK inhibitors have shown impressive efficacy in clinical trials and real-world settings, particularly in ALK-positive NSCLC. They have been associated with higher response rates and longer progression-free survival compared to traditional chemotherapy. However, the development of resistance to first-generation ALK inhibitors is a challenge, leading to the development of newer agents that can overcome these resistance mechanisms.
